MedTrace Logo

Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT

NCT01779882 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2018-03-02

No results posted yet for this study

Summary

The aim of this study is to test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.

Conditions

  • Myeloid Leukemia
  • Precursor Myeloid Neoplasms
  • Lymphoid Neoplasms

Interventions

DRUG

Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation

Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.

DRUG

Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation

Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.

Sponsors & Collaborators

  • University Hospital, Zürich

    collaborator OTHER

  • University Hospital, Geneva

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Nathan Cantoni, MD · Kantonsspital Aarau, Switzerland

  • Sabine Gerull, MD · University Hospital, Basel, Switzerland

  • Gayathri Nair, MD · University Hospital, Zürich

  • Yves Chalandon, MD · University Hospital Geneva, Switzerland

  • Jakob Passweg, MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2018-01-06
Completion
2018-01-06

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01779882 on ClinicalTrials.gov